erlotinib hydrochloride has been researched along with peoniflorin in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (peoniflorin) | Trials (peoniflorin) | Recent Studies (post-2010) (peoniflorin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 795 | 4 | 563 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, XL; Guo, LM; Hao, J; Ji, W; Wu, XZ; Yang, X; Zhou, T; Zhu, CH | 1 |
1 other study(ies) available for erlotinib hydrochloride and peoniflorin
| Article | Year |
|---|---|
Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glucosides; Humans; Mice; Mice, Nude; Monoterpenes; Pancreatic Neoplasms; Phosphorylation; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2016 |